gimeracil,tegafur,nivolumab,capecitabine,oxaliplatin,oteracil
otsuka,bms,nordic group,ono pharma
['nivolumab', 'nivo', 'attraction-5']
ono pharma presented the results of attraction-5 study at the 2023. as per the update, nivolumab + chemotherapy vs. placebo + chemotherapy in patients with pstage iii g/gej cancer did not meet the primary endpoint of rfs. click here to know more: 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry